Printer Friendly

PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin.

M2 EQUITYBITES-May 26, 2017-PharmaMar signs licensing agreement in Turkey with EczacA[+ or -]baAYA[+ or -] for anticancer drug Aplidin

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Healthcare company PharmaMar (MCE:PHM) stated on Thursday that it plans to commercialise the marine-derived anticancer drug Aplidin (plitidepsin) in Turkey in a licensing agreement with Eczac?bas? Group.

This agreement will provide PharmaMar with an upfront payment as well as development milestones related to the health approval procedure of Aplidin in Turkey.

In conjunction with the agreement, PharmaMar will retain exclusive production rights and will supply the finished product to Eczac?bas? for commercial use.

According to PharmaMar, Aplidin is its second most advanced anticancer drug that is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma.

The company stated that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i] and in September 2016. It has submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for plitidepsin in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM).

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 26, 2017
Words:193
Previous Article:Brinker International's board approves 6% higher dividend of USD0.34 per share.
Next Article:Allstate announces common and preferred stock dividends.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |